Enzalutamide

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hormone-refractory Prostate Cancer

Conditions

Hormone-refractory Prostate Cancer

Trial Timeline

Feb 5, 2015 → Jul 22, 2019

NCT ID

NCT02288936

About Enzalutamide

Enzalutamide is a phase 2 stage product being developed by Astellas Pharma for Hormone-refractory Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02288936. Target conditions include Hormone-refractory Prostate Cancer.

What happened to similar drugs?

0 of 2 similar drugs in Hormone-refractory Prostate Cancer were approved

Approved (0) Terminated (0) Active (2)

🔄amg 162AmgenPhase 3

🔄DenosumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05404139	Phase 2	Recruiting	May 24, 2023	Mar 1, 2026	Metastatic Prostate Cancer
NCT02749903	Phase 2	Active	Sep 14, 2016	Jul 5, 2028	Salivary Cancer
NCT02799745	Phase 2	Completed	Jun 9, 2016	Aug 28, 2020	Prostate Cancer
NCT02750358	Phase 2	Active	May 19, 2016	May 1, 2026	Breast Cancer
NCT02605863	Phase 2	Terminated	Jan 1, 2016	Feb 1, 2018	Bladder Cancer
NCT02384382	Phase 2	Completed	Nov 30, 2015	May 3, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02441517	Approved	Terminated	Oct 28, 2015	Mar 15, 2017	Metastatic Castration Resistant Prostate Cancer
NCT02507570	Phase 2	Completed	Sep 23, 2015	Jan 18, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02495974	Pre-clinical	Completed	Sep 8, 2015	Feb 8, 2019	Metastatic Castration Resistant Prostate Cancer
NCT02203695	Phase 2	Completed	Mar 28, 2015	Dec 31, 2022	Adenocarcinoma of the Prostate
NCT02288936	Phase 2	Completed	Feb 5, 2015	Jul 22, 2019	Hormone-refractory Prostate Cancer
NCT02669771	Pre-clinical	Completed	Nov 30, 2014	Nov 30, 2018	Castration-resistant Prostate Cancer
NCT02124668	Phase 2	Completed	Sep 23, 2014	May 25, 2017	Castration-Resistant Prostate Cancer
NCT03297385	Phase 2	Completed	Aug 28, 2014	Apr 1, 2017	Prostate Cancer
NCT02116582	Approved	Completed	May 23, 2014	Sep 29, 2017	Metastatic Castration-Resistant Prostate Cancer
NCT02099864	Phase 2	Completed	Feb 5, 2014	Jul 8, 2024	Castration-Resistant Prostate Carcinoma
NCT01977651	Approved	Completed	Sep 25, 2013	Jan 11, 2019	Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02138162	Phase 1	Completed	Aug 1, 2013	Mar 1, 2014	Severe Hepatic Impairment
NCT01889238	Phase 2	Completed	Jun 12, 2013	Jan 10, 2024	Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
NCT01663415	Phase 2	Withdrawn	Aug 1, 2012	Oct 1, 2014	Metastatic Castration-Resistant Prostate Cancer

Competing Products

8 competing products in Hormone-refractory Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
YM598	Astellas Pharma	Phase 2	27
Zoledronic acid + Estramustine + Docetaxel	Novartis	Phase 2	35
amg 162	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40
IV Bisphosphonate q 4 weeks	Amgen	Phase 2	35
Dasatinib	Bristol Myers Squibb	Phase 2	35
ILX651	Sanofi	Phase 2	35
VIR-5500	Vir Biotechnology	Phase 1	30